13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001496201
Total reported value
$766.5M
$766.5M
113 檔
22.9%
As reported in its official Q2 2024 Form 13F filing, Sphera Funds Management LTD.'s tracked investment portfolio stood at $766.5M with 113 total positions.
In Q2 2024, Sphera Funds Management LTD. displayed an active expansion posture, initiating 16 new positions and adding to 12 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 8.99% | +1.19% | -19.20% | |
| 2 | SMH | Vaneck Semiconductor ETF | ETF-Other | 5.33% | — | — | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.85% | -0.51% | +75.27% | |
| 4 | SNY | Sanofi-adr | Stock-Healthcare | 2.97% | -0.56% | -10.01% | |
| 5 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.84% | +0.43% | +36.66% | |
| 6 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 2.67% | -1.06% | EXIT | |
| 7 | NICE | Nice LTD - Spon Adr | Stock-Tech | 2.66% | -0.10% | EXIT | |
| 8 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.30% | +0.20% | +1.12% | |
| 9 | META | Meta Platforms Inc-class A | Stock-Comm Services | 2.30% | — | +31.45% | |
| 10 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 2.13% | — | +77.40% | |
| 11 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.02% | +0.55% | NEW | |
| 12 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.02% | — | — | |
| 13 | MSFT | Microsoft CORP | Stock-Tech | 2.01% | — | +19.53% | |
| 14 | AAPL | Apple Inc | Stock-Tech | 1.77% | — | +251.43% | |
| 15 | KURA | Kura Oncology Inc | Stock-Other | 1.72% | +0.04% | — | |
| 16 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.65% | -0.13% | +0.10% | |
| 17 | LLY | Eli Lilly & Co | Stock-Healthcare | 1.63% | -0.06% | -7.05% | |
| 18 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.56% | -0.06% | +11.65% | |
| 19 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 1.52% | +0.05% | -6.02% | |
| 20 | BIIB | Biogen Inc | Stock-Healthcare | 1.50% | +2.85% | -32.89% | |
| 21 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 1.50% | — | — | |
| 22 | SKYE | Skye Bioscience Inc | Stock-Other | 1.42% | -0.01% | — | |
| 23 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.41% | — | -10.10% | |
| 24 | JNJ | Johnson & Johnson | Stock-Healthcare | 1.39% | -0.16% | -12.53% | |
| 25 | ASML | ASML Holding N.V. | Stock-Tech | 1.38% | — | — | |
| 26 | ✓ | Merus N V | Stock-Other | 1.19% | — | -1.14% | |
| 27 | CRM | Salesforce Inc | Stock-Tech | 1.18% | — | — | |
| 28 | ✓ | Immatics NV | Stock-Other | 1.16% | -0.14% | +9.76% | |
| 29 | CATX | Perspective Therapeutics Inc | Stock-Other | 1.07% | — | — | |
| 30 | PHVS | Pharvaris N.V. | Stock-Other | 1.03% | — | +2.64% | |
| 31 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.01% | +0.05% | -42.47% | |
| 32 | RZLT | Rezolute Inc | Stock-Other | 1.00% | — | +71.36% | |
| 33 | CYBNEUR | Cybin Inc | Stock-Other | 0.95% | — | — | |
| 34 | VIGL | Vigil Neuroscience Inc | Stock-Other | 0.92% | — | -2.21% | |
| 35 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.91% | — | — | |
| 36 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.89% | — | +6.54% | |
| 37 | ABBV | Abbvie Inc | Stock-Healthcare | 0.89% | -0.05% | — | |
| 38 | PANW | Palo Alto Networks Inc | Stock-Tech | 0.83% | -1.34% | EXIT | |
| 39 | S | Sentinelone Inc -class A | Stock-Tech | 0.81% | — | -48.48% | |
| 40 | TSEM | Tower Semiconductor Ltd. | Stock-Tech | 0.80% | -0.38% | -16.70% | |
| 41 | AMAT | Applied Materials Inc | Stock-Tech | 0.79% | +1.04% | NEW | |
| 42 | ENPH | Enphase Energy Inc | Stock-Tech | 0.77% | -0.86% | EXIT | |
| 43 | NVS | Novartis Ag-sponsored Adr | Stock-Healthcare | 0.73% | +0.12% | — | |
| 44 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.73% | +0.27% | +45.57% | |
| 45 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.71% | -0.59% | -32.79% | |
| 46 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.69% | — | +49.56% | |
| 47 | MU | Micron Technology Inc | Stock-Tech | 0.66% | — | — | |
| 48 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.65% | — | -29.43% | |
| 49 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 0.61% | — | — | |
| 50 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.61% | — | +12.63% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SMH | Vaneck Semiconductor ETF | +5.3% | NEW | New buy |
| 2 | QQQ | Invesco Qqq Trust Series 1 | +1.5% | NEW | New buy |
| 3 | SKYE | Skye Bioscience Inc | +1.4% | NEW | New buy |
| 4 | ASML | ASML Holding N.V. | +1.4% | NEW | New buy |
| 5 | AAPL | Apple Inc | +1.4% | +251.43% | Add |
| 6 | AMZN | Amazon.com Inc | +1.3% | +86.35% | Add |
| 7 | CRM | Salesforce Inc | +1.2% | NEW | New buy |
| 8 | SRPT | Sarepta Therapeutics Inc | +1.1% | +77.40% | Add |
| 9 | BBIO | Bridgebio Pharma Inc | +1.1% | +75.27% | Add |
| 10 | CATX | Perspective Therapeutics Inc | +1.1% | NEW | New buy |
| 11 | IONS | Ionis Pharmaceuticals Inc | +0.9% | NEW | New buy |
| 12 | PANW | Palo Alto Networks Inc | +0.8% | NEW | New buy |
| 13 | MU | Micron Technology Inc | +0.7% | NEW | New buy |
| 14 | RZLT | Rezolute Inc | +0.6% | +71.36% | Add |
| 15 | META | Meta Platforms Inc-class A | +0.6% | +31.45% | Add |
| 16 | LRCXEUR | Lam Research CORP | +0.5% | NEW | New buy |
| 17 | SVRA | Savara Inc | +0.5% | NEW | New buy |
| 18 | PRAX | Praxis Precision Medicines I | +0.5% | +102.34% | Add |
| 19 | ELDN | Eledon Pharmaceuticals Inc | +0.5% | NEW | New buy |
| 20 | NTLA | Intellia Therapeutics Inc | +0.4% | NEW | New buy |
| 21 | ADI | Analog Devices Inc | +0.4% | NEW | New buy |
| 22 | PTCT | Ptc Therapeutics Inc | +0.4% | NEW | New buy |
| 23 | MSFT | Microsoft CORP | +0.4% | +19.53% | Add |
| 24 | KLAC | Kla CORP | +0.4% | NEW | New buy |
| 25 | HOWL | Werewolf Therapeutics Inc | -0.4% | — | Unchanged |
| 26 | OTLK | Outlook Therapeutics Inc | -0.4% | -0.00% | Trim |
| 27 | ALNY | Alnylam Pharmaceuticals Inc | -0.4% | EXIT | Sold out |
| 28 | SNDX | Syndax Pharmaceuticals Inc | -0.4% | +1.12% | Add |
| 29 | TBLA | Taboola.com Ltd. | -0.4% | -43.97% | Trim |
| 30 | VTYXUSD | Ventyx Biosciences Inc | -0.5% | +2.01% | Add |
| 31 | WIX | Wix.com Ltd. | -0.5% | -52.39% | Trim |
| 32 | NICE | Nice LTD - Spon Adr | -0.5% | +32.23% | Add |
| 33 | DAWNGBX | Day One Biopharmaceuticals I | -0.5% | -29.43% | Trim |
| 34 | MLYS | Mineralys Therapeutics Inc | -0.5% | -32.79% | Trim |
| 35 | CYBNEUR | Cybin Inc | -0.5% | — | Unchanged |
| 36 | ✓ | Inozyme Pharma Inc | -0.6% | +6.54% | Add |
| 37 | BIIB | Biogen Inc | -0.6% | -32.89% | Trim |
| 38 | SEDG | Solaredge Technologies Inc | -0.7% | EXIT | Sold out |
| 39 | JSPR | Jasper Therapeutics Inc | -0.7% | -10.10% | Trim |
| 40 | INCY | Incyte CORP | -0.7% | EXIT | Sold out |
| 41 | GLBE | Global-E Online Ltd. | -0.7% | -67.97% | Trim |
| 42 | FROG | JFrog Ltd. | -0.8% | -47.46% | Trim |
| 43 | CAMT | Camtek Ltd. | -0.9% | -97.41% | Trim |
| 44 | NVMI | Nova Ltd. | -0.9% | EXIT | Sold out |
| 45 | MRK | Merck & Co. Inc. | -0.9% | -42.47% | Trim |
| 46 | TEVA | Teva Pharmaceutical-sp Adr | -1% | -19.20% | Trim |
| 47 | S | Sentinelone Inc -class A | -1% | -48.48% | Trim |
| 48 | ✓ | Fusion Pharmaceuticals Inc | -1.4% | EXIT | Sold out |
| 49 | ISREUR | Isoray Inc | -2.1% | EXIT | Sold out |
| 50 | XBI | Ss Spdr S&p Biotech ETF | -5.1% | EXIT | Sold out |
According to official SEC Form 13F filings, Sphera Funds Management LTD. reported a total U.S. public equity portfolio value of $766.5M across 113 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TEVA, SMH, BBIO) accounted for 22.9% of total reported equity market value during Q2 2024.
Top New Position Initiated
SMH
市值: $39.1M
Top Position Liquidated / Trimmed
XBI
前期市值: $36.1M
During Q2 2024, Sphera Funds Management LTD.'s top holdings by market value included TEVA (9.0%)、SMH (5.3%)、BBIO (3.9%). The largest single position, TEVA, represented 9.0% of total portfolio value.
In Q2 2024, Sphera Funds Management LTD. made 48 total portfolio adjustments, initiating 16 new buys, adding to 12 positions, trimming 13 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.